Implanet SA (ALIMP) AI Stock Analysis

• Market Cap: €34.23M
• Dividend Yield: N/A
• Average Volume (3M): 332.66K
• Price to Earnings (P/E): ―
• Beta (1Y): 0.63
• Revenue Growth: 52.11%
• EPS Growth: 68.65%
• Country: FR
• Employees: 46
• Sector: Healthcare
• Sector Strength: 45
• Industry: Medical - Devices
• EPS (TTM): -0.02
• Shares Outstanding: 143,818,970
• 10 Day Avg. Volume: 485,065
• 30 Day Avg. Volume: 332,657
• PEG Ratio: 0.04
• Price to Book (P/B): 18.30
• Price to Sales (P/S): 1.41
• P/FCF Ratio: -4.73
• Enterprise Value/Market Cap: N/A
• Enterprise Value/Revenue: N/A
• Enterprise Value/Gross Profit: N/A
• Enterprise Value/Ebitda: N/A
• 1Y Price Target: N/A
• Price Target Upside: N/A
• Rating Consensus: N/A
• Number of Analyst Covering: 0
• EPS Forecast (FY): N/A
• Revenue Forecast (FY): N/A

• Rating: 47 Neutral
• Price Target: €0.25 ▼(-5.38% Downside)

The score is held back primarily by weak financial performance (ongoing losses, high leverage/very low equity, and negative operating/free cash flow). Technical indicators provide a partial offset with improving momentum, while valuation remains constrained by negative earnings and no dividend support.

Positive Factors

Product portfolio & market focus

Implanet’s focused product set—vertebral fixation systems and orthopedic implants—targets hospitals and surgical centers where demand is structural. Specialization supports durable clinical adoption, clearer R&D priorities, and deeper relationships with surgeons and distributors over the medium term.

Strong recent revenue growth

A ~52% reported revenue growth indicates successful market traction and expanding product uptake. If sustained, this growth can help scale fixed costs, improve bargaining with suppliers and distributors, and create a foundation for improving margins and funding incremental R&D without relying solely on financing.

Improving gross margins

Improving gross margin signals better pricing power or lower product costs, which are key to long-term margin sustainability in medical devices. Higher gross margins enable reinvestment in R&D and commercialization, increasing chances of moving toward positive EBIT if maintained alongside revenue growth.

Negative Factors

High leverage and weak equity

A highly leveraged balance sheet with minimal or negative equity reduces resilience to revenue shocks and increases refinancing risk. Over months, leverage constrains strategic flexibility, raises interest burdens, and can force dilutive financing if operating trends do not rapidly improve.

Persistent negative operating and free cash flow

Ongoing negative OCF and free cash flow indicate the business cannot internally fund operations or growth. Medium-term reliance on external financing exposes the company to capital market cycles, potentially limiting investment in sales, inventory, or R&D and risking liquidity stress if funding tightens.

Consistent unprofitability at EBIT and net levels

Sustained negative EBIT and net losses reflect operational challenges and cost structure issues. Without a clear path to sustained profitability, the firm may struggle to generate retained earnings for reinvestment, undermining long-term competitiveness and increasing dependence on external capital.

Implanet SA Business Overview & Revenue Model

Company Description

Implanet SA (ALIMP) is a French medical technology company specializing in the development and commercialization of innovative implants and associated surgical instruments for orthopedic and spinal surgery. The company focuses on providing advanced solutions to enhance patient outcomes and improve surgical efficiency, with a product portfolio that includes vertebral fixation systems and orthopedic implants tailored for various surgical applications.

How the Company Makes Money

Implanet generates revenue primarily through the sale of its orthopedic and spinal implant products to hospitals and surgical centers. Key revenue streams include direct sales of surgical implants and instrumentation, as well as potential recurring revenue from maintenance and support services. The company may also benefit from partnerships with medical device distributors and collaborations with healthcare providers to expand its market reach. Additionally, Implanet's investments in research and development could lead to new product innovations, further contributing to its financial growth.

Implanet SA Financial Statement Overview

Summary

Implanet SA faces significant financial challenges with consistent operational losses and reliance on debt financing. While recent revenue growth is promising, profitability remains elusive. The high leverage and negative equity expose the company to financial risks, necessitating strategic improvements in cost management and operational efficiency.

Income Statement

Implanet SA shows a fluctuating revenue trend with a recent uptick from 2023 to 2024. However, the company consistently reports negative EBIT and net income, indicating operational challenges and a lack of profitability. Gross profit margin has improved, but negative net profit and EBIT margins highlight ongoing struggles with cost management and profitability.

Balance Sheet

The balance sheet reveals a high debt-to-equity ratio due to substantial debt levels and low stockholders' equity, which was negative in 2023. The equity ratio is minimal, indicating financial instability. The company’s assets are heavily leveraged, which may pose risks if revenue growth does not sustain.

Cash Flow

Cash flow analysis indicates persistent negative operating and free cash flows, revealing liquidity issues. Free cash flow growth was negative, and the operating cash flow to net income ratio reflects operational inefficiencies. Financing activities are crucial for liquidity, but reliance on external funding may not be sustainable long-term.

Breakdown	TTM	Dec 2024	Dec 2023	Dec 2022	Dec 2021	Dec 2020
Income Statement
Total Revenue	11.10M	9.41M	7.45M	8.03M	6.14M	3.89M
Gross Profit	4.81M	4.10M	3.13M	3.91M	2.74M	1.59M
EBITDA	-3.49M	-3.82M	-5.08M	-2.46M	-3.26M	-1.46M
Net Income	-4.81M	-4.37M	-6.68M	-3.54M	-4.61M	-3.98M
Balance Sheet
Total Assets	16.53M	14.89M	10.64M	14.47M	16.70M	8.70M
Cash, Cash Equivalents and Short-Term Investments	502.00K	1.60M	248.00K	531.00K	1.87M	1.14M
Total Debt	6.12M	6.50M	6.15M	6.80M	9.61M	4.66M
Total Liabilities	17.90M	14.16M	10.81M	10.93M	13.90M	7.68M
Stockholders Equity	-1.36M	727.00K	-174.00K	3.54M	2.80M	1.02M
Cash Flow
Free Cash Flow	-1.23M	-2.81M	-2.17M	-3.04M	-3.91M	-3.29M
Operating Cash Flow	-279.00K	-2.32M	-1.45M	-2.47M	-3.52M	-3.07M
Investing Cash Flow	-1.29M	-844.00K	-768.00K	-570.00K	1.57M	-53.00K
Financing Cash Flow	982.00K	4.37M	1.95M	1.60M	2.73M	3.77M

Implanet SA Technical Analysis

• Technical Analysis Sentiment: Positive
• Last Price: 0.26
• 50DMA: Positive
• 100DMA: Negative
• 200DMA: Positive
• MACD: Negative
• RSI: Neutral
• STOCH: Neutral

Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For FR:ALIMP, the sentiment is Positive. The current price of 0.26 is above the 20-day moving average (MA) of 0.21, above the 50-day MA of 0.21, and above the 200-day MA of 0.18, indicating a bullish trend. The MACD of <0.01 indicates Negative momentum. The RSI at 58.63 is Neutral, neither overbought nor oversold. The STOCH value of 49.96 is Neutral, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Positive sentiment for FR:ALIMP.

Implanet SA Peers Comparison

Name	Overall Rating	Market Cap	P/E Ratio	ROE	Dividend Yield	Revenue Growth	EPS Growth
Sector *	51 Neutral	$7.86B	-0.30	-43.30%	2.27%	22.53%	-2.21%
ALIKO	50 Neutral	€25.66M	-6.86	-16.42%	―	138.92%	11.14%
ALIMP	47 Neutral	€34.23M	-6.26	-450.14%	―	52.11%	68.65%
ALMDT	47 Neutral	€153.54M	-3.59	―	―	6.75%	15.48%
ALTHE	45 Neutral	€35.47M	-4.77	-2351.12%	―	-4.70%	-64.31%